Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer

Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1586/erp.13.13

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal /economics /therapeutic use; Cost-Benefit Analysis; Follicle Stimulating Hormone /metabolism; Gonadotropin-Releasing Hormone /antagonists & inhibitors; Humans; Leuprolide /economics /therapeutic use; Luteinizing Hormone /metabolism; Male; Markov Chains; Oligopeptides /economics /therapeutic use; Prostatic Neoplasms /drug therapy /economics /pathology; Quality-Adjusted Life Years; Testosterone /metabolism

AccessionNumber
22013015392

Date bibliographic record published
25/04/2013